GPR84 Antagonist Compounds for Targeted Inflammation Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for conditions associated with GPR84, such as inflammatory diseases, pain, neuroinflammatory conditions, neurodegenerative diseases, autoimmune diseases, metabolic diseases, cardiovascular diseases, leukemia, and fibrotic diseases like NASH and IPF, lack effective antagonists to target GPR84 receptor activity.
Innovation Solution
Development of compounds that act as antagonists to GPR84, inhibiting its activity and reducing associated biological activities, including Gai signaling and proinflammatory cytokine secretion, with potential applications in pharmaceutical compositions for treating various disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If GPR84 is upregulated in inflammatory conditions to mediate immune responses, then immune cell function is enhanced, but excessive inflammation and tissue damage occur
Solution Approach 1:
The patent applies preliminary anti-action by developing GPR84 antagonist compounds that pre-block the receptor before excessive inflammatory responses occur. The compounds (e.g.,Formula I structures with specific ring systems and substituents) bind to GPR84 in advance, preventing ligand-induced overactivation and subsequent tissue damage while maintaining necessary immune surveillance functions.
Solution Approach 2:
The patent employs parameter changes by modifying the inflammatory response threshold through GPR84 antagonism. The compounds alter the activation parameters of immune cells by blocking GPR84 signaling, thereby changing the balance between protective immunity and harmful inflammation. This allows the system to maintain immune competence while reducing pathological inflammatory responses.
2Object-generated harmful factors
If current anti-inflammatory therapies are used, then inflammation is reduced, but they lack specificity and cause broad immunosuppression
Solution Approach 1:
The patent uses GPR84 as a specific intermediary target rather than broad immunosuppressants. The antagonist compounds selectively bind to GPR84 expressed on specific immune cell populations (neutrophils, monocytes, macrophages), providing targeted modulation of inflammatory responses while preserving overall immune function. This intermediary approach allows precision control over inflammation without global immunosuppression.
Solution Approach 2:
The patent applies local quality by targeting GPR84 expression specifically on certain immune cell types and tissues involved in inflammation. The compounds exert their effect locally at sites of GPR84 expression (immune cells, inflamed tissues) rather than systemically suppressing all immune functions. This localized action maintains immune competence in non-inflammatory contexts while controlling pathological inflammation.
3Adaptability or versatility
If GPR84 antagonists are developed for specific inflammatory diseases, then disease-specific treatment is achieved, but development complexity and time increase
Solution Approach 1:
The patent achieves universality by developing GPR84 antagonist compounds with a core structure (Formula I) that can treat multiple GPR84-mediated diseases across different organ systems. The same compound class addresses inflammatory bowel disease, pulmonary fibrosis, autoimmune conditions, and other inflammatory disorders, reducing development complexity compared to disease-specific therapies while maintaining adaptability to various clinical indications.
Data Source
AI summary
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of GPR84, and the treatment of GPR84-mediated disorders.